These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 11914891

  • 1. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, Maes A, Mortelmans L.
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [Abstract] [Full Text] [Related]

  • 2. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Takekuma M, Maeda M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [Abstract] [Full Text] [Related]

  • 3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 4. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
    Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, Peeters M, De Leyn P, Van Raemdonck D, Mortelmans L.
    J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Malignant tumor with false negative 18F-FDG PET image].
    Dong MJ, Lin XT, Zhao J, Guan YH, Zuo CT, Chen X, Dai JZ, Jiang BD.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour.
    Graziosi L, Bugiantella W, Cavazzoni E, Cantarella F, Porcari M, Baffa N, Donini A.
    Ann Ital Chir; 2011 Sep; 82(2):125-9. PubMed ID: 21682102
    [Abstract] [Full Text] [Related]

  • 13. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK.
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
    Sun SS, Chen TC, Yen RF, Shen YY, Changlai SP, Kao A.
    Anticancer Res; 2001 Mar; 21(4B):2957-61. PubMed ID: 11712793
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
    Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, Ruers TJ.
    J Clin Oncol; 2002 Nov 15; 20(22):4453-8. PubMed ID: 12431968
    [Abstract] [Full Text] [Related]

  • 17. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M, Ruiz G, Montz R, Carreras JL.
    Q J Nucl Med; 2002 Jun 15; 46(2):113-21. PubMed ID: 12114874
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY, Liang JA, Chen YK, Tsai CY, Kao CH.
    Hepatogastroenterology; 2006 Jun 15; 53(69):348-50. PubMed ID: 16795969
    [Abstract] [Full Text] [Related]

  • 20. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S.
    Eur J Nucl Med Mol Imaging; 2002 Jul 15; 29(7):915-21. PubMed ID: 12111132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.